Merkel cell carcinoma - A retrospective case series

Kanica Chaudhary*,1, Jay Mehta*, Shilpa Prabhudesai*, Vinita Pant*, Puja Khanna* and Anita Borges

* Centre for Oncopathology, Rectifier house, 3rd, 570, Naigaon cross road, Wadala, Mumbai 400031.

ABSTRACT Merkel cell carcinoma (MCC) is a rare cutaneous malignancy. Excessive exposure to sunlight and ultraviolet (UV) radiation, immune suppression and advanced age are the major risk factors for MCC. It typically presents in the head and neck region (50%), followed by extremities (40%) and rarely at other sites (<10%). In 2008, Merkel cell polyomavirus (MCV) was linked to the development of Merkel cell carcinoma (MCC). MCC is included in the differential diagnosis of small blue cell neoplasms, composed of monomorphous population of cells with round-to-oval nucleus and scant cytoplasm. The tumor cells co-express epithelial and neuroendocrine markers. ALK (Anaplastic lymphoma kinase) expression is frequently seen in MCC and correlates with the etiopathology of Merkel cell polyomavirus (MCV).

On a retrospective search through our database, we found ten cases of MCC over a period of three years from 2016 to 2019. Three of the ten cases were at sites of chronic sun exposure. Eight of the ten patients were male. Two of the ten patients had recurrences; one within a year. Five of the ten patients had metastatic disease. All ten cases showed immunoexpression of CK20, Synaptophysin and Chromogranin. ALK-1 expression could be ascertained in six of the cases and was positive in all of them. This case series highlights a relatively uncommon Polyoma virus associated carcinoma. The significance of ALK immunopositivity in MCC, its implied correlation with Merkel cell polyomavirus (MCV) etiopathogenesis and the possibility to use it as a novel therapeutic target needs further exploration.

KEYWORDS Merkel cell carcinoma (MCC), Merkel cell polyoma virus (MCV), ALK (Anaplastic lymphoma kinase)

Introduction

Merkel, a professor of anatomy at the University of Rostock, Germany, described “Tastzellen” (touch cells)—later known as Merkel cells—in the epidermis of domestic animals and humans, for the first time in 1875[1]. In 1972, Toker first reported a case series study of five patients with “trabecular carcinoma” and recognized a “distinct pathological entity”[2]. It took Tang and Toker another six years to determine that trabecular carcinoma “most probably” derives from Merkel cells[3].

The Merkel cell is a specialized neuroepithelial cell that may have a touch receptor function and is present within the basal cell layer of the epidermis, oral mucosa, outer follicular sheath of hair follicles and sweat ducts[4].

Merkel cell carcinoma is a highly aggressive neuroendocrine skin tumour that typically presents as a rapidly growing, painless, flesh-coloured or bluish-red intracutaneous nodule. The most common clinical features of MCC are summarized by the acronym “AEIOU”: Asymptomatic, Expanding rapidly, Immune suppression, Older than age 50 and UV-exposed site on a fair-skinned individual. The most frequent sites of involvement are in the head and neck region (50%), followed by extremities (40%) and rarely at other sites (<10%)[5-8].

In 2008, Merkel cell polyomavirus (MCV) was linked to the development of MCC[9]. Clonal integration of MCV DNA into the host genome is a causal factor for the development of the majority of MCC tumors[10]. MCV is an abundant virus frequently detected on healthy human skin, suggesting that its infection is widespread in the general population[12-14].

MCC is included in the differential diagnosis of small blue cell neoplasms, composed of a monomorphous population of cells with a round-to-oval nucleus and scant cytoplasm. The nucleus contains primitive, diffusely dispersed chromatin and...
mitoses are usually numerous. Three morphological patterns are noted in MCC, i.e. solid, trabecular and diffuse (Figure 1); amongst which the diffuse pattern is most commonly seen[17].

The tumour cells co-express epithelial and neuroendocrine markers. Wide spectrum cytokeratins (AE1/3, CAM5.2) and cytokeratin 20 (CK20) are present typically either as paranuclear dot-like or diffuse cytoplasmic staining. The neuroendocrine markers of MCC include synaptophysin, chromogranin A and others. The closest differential diagnosis is small cell lung carcinoma (SCLC)- which shows TTF-1 expression and is immunonegative for CK20.

ALK immunoexpression is frequently seen in MCC and correlates with the etiopathology Merkel cell polyomavirus (MCV)[18]. ALK expression is absent or very low in normal skin. There are three different anaplastic lymphoma kinase antibody clones (D5F3, 5A4, and anaplastic lymphoma kinase 1)[20-23]. Previous IHC studies suggest that D5F3 is the most sensitive clone in detecting ALK expression in MCC tumors[24]. Studies have further identified ALK as the most frequently over-expressed gene among 50 cancer-related genes in MCC cases[23]. Interestingly, the authors found no evidence of fusion events, raising the possibility that ALK overexpression in Merkel cell carcinoma arises from genetic or epigenetic events[24].

Materials and Methods

On a retrospective search through our database, we found ten cases of MCC over three years from January 2016 to January 2019. We searched our electronic patient database using the following keywords: “Merkel cell carcinoma” and “Merkel cell”. Inclusion criteria were confirmed histopathologic diagnosis of Merkel cell carcinoma. Both biopsy and excision specimens were included. For each patient, the following parameters were assessed: site of involvement, age, sex, recurrence, metastasis, ALK expression on immunohistochemistry (IHC), treatment modality and overall survival. ALK-1 clone was used for IHC.

Case reports

The retrospective search yielded ten cases, the details of which are enumerated herewith. The case table attached summarizes the ten cases with their demographics and disease status.
Table 1

| Case no. | Age(in years)/Sex | Site of involvement         | Treatment modality                        | Recurrence | Metastasis       | ALK expression | Overall survival                  |
|----------|-------------------|-----------------------------|-------------------------------------------|------------|-----------------|----------------|-----------------------------------|
| 1.       | 86/M              | Left thigh                  | Wide local excision                       | No         | No              | N/A            | Remission since 2 years           |
| 2.       | 51/M              | Right hip                   | Wide local excision followed by chemotherapy and radiotherapy | No         | No              | N/A            | Remission since 2 years           |
| 3.       | 87/F              | Left upper eyelid           | Wide local excision                       | Yes (within <2years) | Yes (to lymph nodes) | N/A            | Death (due to co-morbidity)       |
| 4.       | 71/M              | Scalp                       | Wide local excision followed by chemotherapy | Yes- twice (within <1year) | Yes (to lymph nodes) | N/A            | Recurrent disease on the scalp-on treatment |
| 5.       | 65/M              | Right abdominal wall nodule | Wide local excision followed by chemotherapy | No         | No              | Positive       | Remission since 1 year            |
| 6.       | 82/M              | Left inguinal lymph node- primary site unknown | Excision biopsy | Patient lost to follow up | Yes (metastatic lymph node) | Positive       | Patient lost to follow-up         |
| 7.       | 55/F              | Right upper eyelid          | Wide local excision followed by chemotherapy and radiotherapy | No         | No              | Positive       | Ongoing treatment                |
| 8.       | 65/M              | Right parotid region        | Wide local excision                       | No         | Yes (to lymph nodes) | Positive       | Remission                         |
| 9.       | 63/M              | Deep axillary mass          | Wide local excision                       | No         | Yes (to lymph nodes) | Positive       | Ongoing treatment                |
| 10.      | 51/M              | Axillary Lymph node         | Excision biopsy                           | No         | Yes (to lymph node) | Positive       | Ongoing treatment                |

Results

Three of the ten cases were at sites of chronic sun exposure, three were on the extremities, and two were at uncommon sites. Eight of the ten patients were male. Five of the ten patients had metastatic disease. Two of the ten patients had recurrences; one within a year. One patient expired within a year of the recurrence. All ten cases showed immunoexpression of CK20, Synaptophysin and Chromogranin (Figure 2, 3 and 4). ALK-1 expression could only be ascertained in six of the cases and was positive in all six cases (Figure 5). In three of the cases, primary skin involvement could not be demonstrated.

Discussion

The case series demonstrates concordance with the published literature about MCC being predominantly found in elderly males. The mean age of patients in our cohort was 77 years which corroborates with the published literature. While most cases present in sun-exposed areas, it is also
important to note that this neoplasm may present in areas of minimal sun exposure. In our series, only three lesions were found on sun-exposed areas, while the others were on relatively less sun-exposed areas.

A retrospective study of 85 cases of MCC by Eng TY et al. showed that surgery remains the primary modality for the treatment and adjuvant radiation therapy +/- systemic chemotherapy reduces local recurrence[20]. Standard of surgical care for MCC has traditionally been wide local excision (WLE) and at early stages, surgery alone may be sufficient[21-23].

We report here a single centre retrospective analysis. The demographics of our patient cohort differ from other retrospective reports; there were no immunosuppressed patients, which, however, could be explained by the relatively small patient cohort.

Our results lack statistical significance due to the low number of patients and events. Nevertheless, we believe that increased awareness of MCC is essential to ensure optimal initial management. Failure to do so can lead to a higher number of surgical interventions.

Conclusion

This case series highlights a relatively uncommon Polyoma virus-associated carcinoma. The significance of ALK immunopositivity in MCC, its implied correlation with Merkel cell polyomavirus (MCV) etiopathogenesis and the possibility to use it as a novel therapeutic target needs further exploration.

Compliance with ethical standards

The authors confirm that the work presented complies with ethical standards.

Funding

There was no funding involved.

Conflict of interest

The authors declare that they have no conflict of interest.

Contributions

1. Dr. Kanica Chaudhary: Formulation of the manuscript, corresponding author.
2. Dr. Jay Mehta: Conceptualisation of the study, editing of the manuscript, reporting pathologist of some of the cases included in the study.
3. Dr. Shilpa Prabhdesai: Editing of the manuscript, reporting pathologist of some of the cases included in the study.
4. Dr. Vinita Pant: Reporting pathologist of some of the cases included in the study.
5. Dr. Puja Khanna: Digital images, assisted in the groundwork for the study.
6. Dr. Anita Borges: Head of the institute, reporting pathologist of some of the cases included in the study.

References

1. F. Merkel, “Tastzellen und Tastkörperchen bei den Haustieren und beim Menschen,” Archiv für Mikroskopische Anatomie, vol. 11, no. 1, pp. 636–652, 1875.
2. C. Toker, “Trabecular carcinoma of the skin,” Archives of Dermatology, vol. 105, no. 1, pp. 107–110, 1972.
3. C. K. Tang and C. Toker, “Trabecular carcinoma of the skin. An ultrastructural study,” Cancer, vol. 42, no. 5, pp. 2311–2321, 1978.
4. Lever, pg.21-22.
5. Smith PD, Patterson JW. Merkel cell carcinoma (neuroendocrine carcinoma of the skin), Am J Clin Pathol 2001;11(5 Suppl): S68–S78.
6. Locke, FL, Rollison DE, Sondak VK. Merkel cell carcinoma and immunosuppression: what we still need to know. J Nati Cancer Inst. 2015;107.
7. Sternberg’s Diagnostic Surgical Pathology, 6th edition, Chapter 2, pg. 61.
8. WHO, Skin tumors, Chapter on Neural tumors, Pg.272, edition.
9. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319:1096–1100. This study discovers the presence of MCPyV in 80% of MCC tumors and suggests MCPyV is a contributing factor to MCC tumorigenesis.
10. Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. PLoS Pathog. 2009;5:e1000363.
11. Chang Y, Moore PS. Merkel cell carcinoma: a virus-induced human cancer. Annu Rev Pathol. 2012;7:123–144. This review discusses the genomic organization of MCPyV, the molecular biology and pathology of both MCPyV and MCC, and the epidemiology of MCPyV and MCC.
12. Tolstov YL, Pastrana DV, Feng H, Becker JC, Jenkins FJ, Moschos S, Chang Y, Buck CB, Moore PS. Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays. Int J Cancer. 2009;125:1250–1256. This study shows that, although it was previously unrecognized, MCPyV infection is widespread in the human population, and that MCC patients have elevated MCPyV IgG response compared to controls.
13. Schowalter RM, Pastrana DV, Pumphrey KA, Moyer AL, Buck CB. Merkel cell polyomavirus and two previously unknown polyomaviruses are chronically shed from human skin. Cell Host Microbe. 2010;7:509–515. This study isolated complete, wild-type cloned genomes of MCPyV and also discovered the existence of two previously unknown polyomaviruses, human polyomavirus-6 and human polyomavirus-7.
14. Foulongne V, Sauvage V, Hebert C, Dereure O, Cheval J, Goulil MA, Pariente K, Segondy M, Burguière A, Manuguerra J-C, et al. Human Skin Microbiota: High Diversity of DNA Viruses Identified on the Human Skin by High Throughput Sequencing. PLoS One. 2012;7:e38499.
15. Pastrana DV, Tolstov YL, Becker JC, Moore PS, Chang Y, Buck CB. Quantitation of human seroresponsiveness to Merkel cell polyomavirus. PLoS Pathog. 2009;5:e1000578.

16. Chen T, Hedman L, Mattila PS, Jartti T, Ruuskanen O, Soderlund-Venermo M, Hedman K. Serological evidence of Merkel cell polyomavirus primary infections in childhood. J Clin Virol. 2011;50:125–129.

17. Czapiewski P, Biernat W. Merkel cell carcinoma — Recent advances in the biology, diagnostics and treatment. Int J Biochem Cell Biol (2014), http://dx.doi.org/10.1016/j.biocel.2014.04.023

18. Veija, T., Kero, M., Koljonen, V. and Böhling, T. (2018), ALK and EGFR expression by immunohistochemistry are associated with Merkel cell polyomavirus status in Merkel cell carcinoma. Histopathology. Accepted Author Manuscript. DOI:10.1111/his.13815

19. Racz J, Joshua AM, Lipa JE, Sun A, Wright FC. Merkel Cell Carcinoma. In: Wright CF, Escallon J, Cukier M, Tsang EM, Hameed U, editors. Surgical Oncology Manual. Cham: Springer International Publishing; 2016. p. 189-96.

20. Eng TY, Boersma MG, Fuller CD, Cavanaugh SX, Valenzuela F, Herman TS. Treatment of Merkel cell carcinoma. American journal of clinical oncology. 2004;27(5):510-5.

21. Mann GB, Allen PJ, Coit DG. Merkel cell carcinoma. The Australian and New Zealand journal of surgery. 1999;69(2):87.

22. Boyer JD, Zitelli JA, Brodland DG, D’Angelo G. Local control of primary Merkel cell carcinoma: review of 45 cases treated with Mohs micrographic surgery with and without adjuvant radiation. Journal of the American Academy of Dermatology. 2002;47(6):885-92.

23. Filtenborg-Barnkob BE, Bzorek M. Expression of anaplastic lymphoma kinase in Merkel cell carcinomas. Hum Pathol [Internet]. 2013 Aug 1 [cited 2019 Jan 14];44(8):1656–64. Available from: https://www.sciencedirect.com/science/article/pii/S0046817713000531#aep-article-footnote-id4

24. Veija T, Koljonen V, Böhling T, Kero M, Knuutila S, Sarhadi VK. Aberrant expression of ALK and EZH2 in Merkel cell carcinoma. BMC Cancer. 2017;17(1).